Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW AGM date & closing date for director nominations

The date of the Actinogen 2024 AGM will be Thursday 14 November 2024 at 11am in Sydney. Director nominations close 2 October 2024.

Prospectus released for ACW's $3m SPP

The prospectus dated 20 September 2024 for ACW’s $3.0 million share purchase plan and associated options has been released to the ASX.

ACW CEO presents at Pitt Street Research Conference

ACW’s CEO  Steven Gourlay presents at the Pitt Street Research Conference in Sydney.  His presentation outlines the
attractive therapeutic profile of ACW’s novel small molecule drug Xanamem in treating neurological conditions by controlling brain cortisol and the positive outlook for the Company as it enters late-phase clinical trials.

ACW $11.1m capital raising

ACW has announced an $11.1m capital raising comprising an $8.1m share placement and a $3m share purchase plan. The raising was strongly supported with oversubscriptions from institutional investors and a $1m investment from CEO Steven Gourlay.

Click here to view announcement

ACW FY2024 financial results

Actinogen has released its 2024 financial results and annual report. The attached announcement summarizes how the company is advancing into late-stage clinical development and building on recent positive trial data that demonstrate that Xanamem is clinically active in the brain, as featured in the annual report.

ACW 2024 Annual Report

Actinogen is pleased to announce its financial results for the year ended 30 June 2024.
View the 2024 Annual report using the link below.